Method for detecting severity of atopic dermatitis

Patent metadata

Field	Value
Publication number	US-2023265515-A1
Application number	US-202118015311-A
Country	US
Kind code	A1
Filing date	Jul 9, 2021
Priority date	Jul 10, 2020
Publication date	Aug 24, 2023
Grant date	—

Abstract

Provided are a marker for detecting the severity of atopic dermatitis, and a method for detecting the severity of atopic dermatitis using the marker. The method for detecting the severity of atopic dermatitis in a test subject comprises a step of measuring an expression level of at least one gene selected from the group of 9 genes consisting of CAPN1, NCOR2, PPP1R9B, PLP2, GRN, PPP1R12C, LOC146880, SLC31A1 and SYVN1 or an expression product thereof for a biological sample collected from the test subject.

First claim

1 . A method for detecting severity of atopic dermatitis in a test subject, comprising a step of measuring an expression level of at least one gene selected from the group of 9 genes consisting of SLC31A1, CAPN1, NCOR2, PPP1R9B, PLP2, GRN, PPP1R12C, LOC146880 and SYVN1 or an expression product thereof in skin surface lipids collected from the test subject.

2 . The method according to claim 1 , wherein the severity is severity based on an EASI (Eczema Area and Severity Index) score or an IGA (Investigator's Global Assessment) score.

3 . The method according to claim 2 , wherein the severity is severity based on the EASI score, and the measurement of the expression level is measurement of an expression level of at least one gene selected from the group of 5 genes consisting of CAPN1, NCOR2, PPP1R9B, PLP2 and GRN or an expression product thereof.

4 . The method according to claim 2 , wherein the severity is severity based on the IGA score, and the measurement of the expression level is measurement of an expression level of at least one gene selected from the group of 4 genes consisting of SLC31A1, PPP1R12C, LOC146880 and SYVN1 or an expression product thereof.

5 . The method according to claim 1 , wherein the severity is at least one member selected from the group consisting of no symptom, mild and moderate.

6 . The method according to claim 1 , wherein the expression level of the gene or the expression product thereof is measured as an expression level of mRNA.

7 . (canceled)

8 . The method according to claim 1 , wherein the severity of atopic dermatitis is detected by comparing a measurement value of the expression level with a reference value of the gene or the expression product thereof.

9 .- 12 . (canceled)

Assignees

• Kao Corp

Inventors

• Takada Naoto
• Kuwano Tetsuya
• Inoue Takayoshi

Classifications

• C12Q1/686

  Polymerase chain reaction [PCR] · CPC title

• C12Q1/6837

  using probe arrays or probe chips (C12Q1/6874 takes precedence) · CPC title

• C12Q1/6876

  Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title